Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07487701 · ClinicalTrials.gov registry record · NA
Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study
A NA study of Migraine and Chronic Migraine, Headache, sponsored by Theranica.
- Active
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT07487701: Active NA study of Migraine and Chronic Migraine, Headache, sponsored by Theranica.
NCT07487701 is a NA study of Migraine and Chronic Migraine, Headache that is active but no longer recruiting, run by Theranica. The registered enrollment target is 150 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07487701, a NA study of Migraine and Chronic Migraine, Headache, is active but no longer recruiting, sponsored by Theranica.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited, especially among patients with chronic migraine. Remote electrical neuromodulation (REN) is a non-invasive FDA-cleared wearable device for acute and/or preventive migraine treatment. This study evaluated the real-world efficacy and patient-reported outcomes of preventive REN use over 3 months in chronic migraine population.
Primary Outcome
Change in average number of monthly migraine days (MMD) from baseline to 3-months follow-up questionnaire.
Conditions Studied
Interventions
- DEVICE Nerivio REN device
Study Locations (1)
New Jersey
- Theranica Bio-Electronics Inc - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2026-04-15 |
| Phase | NA |
What the registry record for NCT07487701 still lists
NCT07487701 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Nerivio REN device is the first listed.
NCT07487701 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT07487701 about?
NCT07487701 is a clinical study titled "Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study". Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited, especially among patients with chronic migraine. Remote electrical neuromodulation (REN) is a non-invasive FDA...
What is the current status of trial NCT07487701?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2026-02-20. Estimated completion is 2026-04-15.
What conditions does trial NCT07487701 study?
This clinical trial studies the following conditions: Migraine, Chronic Migraine, Headache.
What interventions are being tested in trial NCT07487701?
The interventions under investigation include: Nerivio REN device (DEVICE).
Who is sponsoring clinical trial NCT07487701?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07487701 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07487701's enrollment target sits among peer trials
150 49th of 102 higher than 53 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI